To expand on other potential targets in neuroblastomas with ATM deficiency, increasing evidence suggests that ATM and the Rad3-related (ATR)-checkpoint kinase 1 (CHK1) axis could be an Achilles’ heel for synthetic lethality. This evidence concerns the gene ATR and neuroblastoma.